Early embryogenesis involves the establishment of cell lineages and territorial specifications resulting in the onset of differential gene activity which must include, at least initially, the expression of region-specific regulatory factors. The genes encoding these factors in turn mediate the pattern of the downstream tissue-specific gene transcription and thereby constitute the fundamental unit in the regulatory circuit that ultimately leads to morphogenetic changes during development. In the avian embryo, the mesodermal precursors of the cardiac muscle have been mapped and the location, morphogenetic movement, and differentiative transition of these cells have been delineated, beginning with the assignment of cardiogenic fate at stage 4 (-"20 h) (21) in gastrulating embryos (16, 34, 35, 47, 58) . As the development proceeds, the precardiac mesodermal cells give rise to a single linear heart tube at about stage 10 (-33 h), at which time the organized myofibrils appear and rhythmic pulsations begin (34, 47) . The molecular aspects of these early embryonic changes, especially during the period from the assignment of cardiogenic fate to the onset of DIFFERENTIAL CARDIAC TRANSCRIPTION FACTOR EXPRESSION   5131 proteins, such as the AT-rich DNA-binding myocyte enhancer factor 2 (MEF-2), which cross-talk with the E-box-binding proteins (8, 15, 18, 52) . The muscle creatine kinase gene is one of several examples for the E-box-mediated regulation of transcription (9, 18, 26, 27, 41) in which both MEF-2, a member of the MADS family of transcription factors (60) , and the HLH proteins are required for activation of transcription (9) . However, in other striated muscle genes, such as the cardiac MLC2 gene, there is no functional E box, and attempts to identify proteins structurally analogous to the MyoD family in cardiac muscle cells have not been successful (43) . Thus, the mechanism for activation of cardiac muscle gene expression remains enigmatic, and it would appear that tissue-specific regulatory factors divergent from the myogenic HLH proteins are involved in activation of cardiogenic program. Specific isoforms of MEF-2-MADS proteins, generated through alternatively spliced RNA, have been identified in both heart and skeletal muscles (60) and are implicated in regulation of cardiac muscle-specific myogenic program (4, 12) . We have recently identified a new transcription factor (BBF-1) in chicken embryonic cardiac muscle which recognizes the MEF-2 binding site in the cardiac MLC2 promoter but is distinguishable from MEF-2 on the basis of immunoprecipitation with an antibody which recognizes MEF-2 but not BBF-1 (61) . Also, unlike MEF-2, which is present in both cardiac and skeletal muscles (18, 42) , BBF embryo, to stage 4, the definitive streak embryo, was based on examination of the appearance and progression of the primitive streak; identification of stage 5 was based on head process formation, that of stage 6 was based on head-fold formation, and stage 7 onwards was identified by the number of somite pairs (Fig. 1) . In addition to the number of somite pairs, the developing heart at stage 10 showed pulsation while straight, and the stage 11 embryo had a bent beating heart tube. The stage 12 embryo was characterized by an S-shaped heart. Stage 12 embryos were grouped together for isolation of the heart tubes. Only the beating heart tubes were excised with tungsten needles and used for the preparation of tissue extract (see below). Gel mobility shift assay. Gel mobility shift assay was done as described earlier (61) . Double-stranded DNA fragments obtained by renaturation of chemically synthesized oligonucleotides were radiolabeled at the 5' end by polynucleotide kinase and [_y-32P]ATP and used for the binding assay. DNA probe (5,000 cpm) and nuclear proteins (5 to 10 ,ug) were incubated in 10 mM HEPES (pH 7.9)-80 mM NaCl-5 mM MgCl2-0.5 mM EDTA-1 mM dithiothreitol-12.5% glycerol at 4°C for 90 min and were separated on the 6% polyacrylamide gel. For competition, the unlabeled DNA in 100-fold excess was added to the reaction mixture before the addition of nuclear extract.
For immunoprecipitation assay, 0.5 RI of preimmune serum or antiserum to RSRFC4 (45) was preincubated with the nuclear extracts for 30 min at 4°C before addition of the DNA probe.
RESULTS
Expression of cardiac and skeletal muscle-specific genes in early embryogenesis. In order to define myogenesis in terms of the onset of tissue-specific expression of cardiac and skeletal genes, we examined single embryos of defined stages by RT-PCR assay (51) to detect the appearance of cardiac and skeletal muscle MLC2 mRNAs with gene-specific DNA primers. As shown in Fig. 2A , the first discernible signals for cardiac (top panel) and skeletal (middle panel) MLC2 mRNAs appear at stages 5 and 8, respectively. No cardiac MLC2 signal was detected before stage 5, even after several additional cycles of amplification. Consistent with the onset of MLC2, cardiac a-actin mRNA was detected at stage 5 and skeletal ct-actin mRNA was detected at stage 7 ( Fig. 2B and C) . On the other hand, the ubiquitous ,-actin mRNA was present as early as stage 1 in the same embryo ( Fig. 2A, bottom panel) . The lack of cross-amplification of skeletal and cardiac cDNAs by the respective DNA primers demonstrates the tissue specificity of the primer sequences used. Multiple embryos of the same stage were examined separately to ensure reproducibility. The amplified products were also sequenced, when necessary, to verify reliability of PCR amplifications (see Materials and Methods) . These data thus demonstrate that the cardiac and skeletal muscle differentiation begins immediately after the assignment of the cell lineages at stages 4 and 7, respectively, in developing embryos and well before the onset of morphological differentiation for the respective muscles. The temporal separation of the two transcriptional events (stage 5 and stage 8) is consistent with the established separation in appearance of the two tissue-specific morphological characteristics (stage 10 and stage 13). To our knowledge, this is the first evidence for the presence of muscle-specific gene transcripts in early precardiogenic and presomatogenic cells of the blastoderm. In a previous study (3, 22) , ventricular MHC was first detected in stage 7 embryos and the presence of ot-actin mRNA was demonstrated in the cardiac tube just prior to myotome formation (53) . Subsequently, it was shown that single cells isolated from the precardiogenic area of stage 4 chicken embryos synthesize cardiac MHCs, but only after 2 days of cultivation in vitro (17) . Fig. 4 for details) . The PCR products were analyzed on a 1.5% agarose gel stained with ethidium bromide as for Fig. 2 . M in panel A and unlabeled lanes in panel B denote 1-kb DNA ladder used as size marker.
Developmental expression of mRNAs for chicken CMD-1 and the MEF-2 family of proteins. The expression of myogenic HLH determination genes has become a criterion for defining the skeletal myogenic lineage, but the cardiogenic counterparts of the MyoD family have not been identified to date. All members of the MyoD family have been detected first in the somites and subsequently in limb buds during muscle fiber formation (53) . In some cases, one or another homolog of the MyoD family has been found just prior to compartmentalization of somites (7, 44) . Using a DNA primer specific for CMD-1 (32), the chicken skeletal muscle homolog of MyoD, we analyzed (Fig. 3A) single blastoderms at defined stages as above and observed that the first signal for CMD-1 can be detected as early as stage 5, i.e., prior to the appearance of the first somite and the onset of transcription of the skeletal MLC2 gene at stage 8 ( Fig. 2A) . This is consistent with the expected role of HLH proteins in programming skeletal myogenesis. The MyoD homolog in Xenopus laevis, XMyoD, was also reported to be present in mesoderm prior to somite formation (25) . Since we did not detect CMD-1 during precardiac developmental stage 4 or earlier, we conclude that CMD-1 is not involved in specification of cardiogenic lineage.
Unlike the MyoD family of proteins, there is no marker available for cardiogenic programming of embryonic cells. Since MEF-2 proteins exist in both cardiac and skeletal muscles, and at least one member of this protein family, BBF-1, is cardiac muscle specific (61), we examined the expression of mRNA for MEF-2 proteins. We have recently isolated a cDNA clone by screening the 72-h chicken embryonic cardiac cDNA expression library (unpublished work) with human RSRFC4 cDNA (45) as probe. Partial sequence of the cDNA clone revealed that it has a significant homology with human MEF-2 cDNA clone (60) (Fig. 4) . Using DNA primers encompassing this domain, we observed (Fig. 3B ) that mRNA transcripts for the MEF-2 family of proteins are present in very early embryos, before the appearance of CMD-1 mRNA, beginning at the pregastrulation stage, stage 2. Although at present it is not possible to distinguish between mRNAs for different members of cardiac MEF-2, the evidence (see below) that functional expression of BBF-1 precedes that of MEF-2 presents a compelling argument that expression of mRNA for BBF-1 must precede that of MEF-2 mRNA.
Differential expression of MEF-2 and BBF-1 DNA-binding activities in early development. To examine the possibility whether the functional expression of BBF-1 and MEF-2 DNAbinding activities is developmentally regulated in harmony with the appearance of MLC2 mRNA, we isolated protein extracts from embryos of defined stages and tested for DNA-protein complex formation in gel mobility shift assay with element B sequence (MEF-2 site) (Fig. 5 ) in cardiac MLC2 promoter as probe. As shown in Fig. 6 , a defined BBF-1-DNA complex appears first at stage 5, with a barely detectable signal at stage 4. The MEF-2-like activity, on the other hand, begins to appear only at stage 8 and becomes defined at stage 12. The origin of an additional faster-moving band at stage 8 is not presently known. MEF-2 complex, on occasion, is known to produce a doublet in gel shift assay. To ascertain whether MEF-2 and BBF-1 from early embryos are the same as those obtained from the differentiated heart muscle, we examined the immunological and DNA recognition properties of these proteins. Figure 7 shows that preincubation of extracts isolated from stage 12 embryos with antibody RSRFC4 (45) eliminated MEF-2 without affecting BBFs, as observed earlier (61 (Fig. 5) . Four major complexes, identified as MEF-2, BBF-1, BBF-2, and BBF-3, bind to the AT-rich core sequence of element B (MEF-2 site) probe. The stages of embryonic development and embryonic ages at which extracts were isolated are indicated on top. Stages were assigned on the basis of correspondence of time of incubation with morphological parameters observed in our laboratory. Competition was done with an oligonucleotide containing MEF-2 sequence (MF2) from the muscle creatine kinase enhancer, or the oligonucleotide containing the mutated element B sequence (AB) and element B-DNA. Extracts were also preincubated either with an antibody against RCSRFC4 (45) or with the preimmune serum prior to gel shift assay with the element B DNA as probe as described in Materials and Methods. stage 12 embryos are the same as those obtained from differentiated heart tissues of 12-day-old embryos. With the MEF-2 site DNA of the muscle creatine kinase promoter as probe and extracts from stages 6 and 9 of chicken embryos, a previous study (33) also noted the presence of a complex, with mobility similar to that of BBF-1, in stage 6 and stage 9 extracts, but the MEF-2-like complex was found only in stage 9 embryos. BBF-2 and BBF-3 are also differentially regulated during development (Fig. 6) . The developmental expression of BBF-2 was similar to that of BBF-1, but BBF-3 was down-regulated after reaching a maximum at about stage 6. The tissue specificity of these proteins, however, is not yet established.
For comparison, we also examined the gel mobility shift patterns in single embryos with another AT-rich DNA (element A), the CArG box (39) , and the TATA box (element C) (Fig. 5 ) in cardiac MLC2 promoter as probes. The appearance of the CArG-binding proteins is also differentially regulated during development with some similarity to that of element B-binding pattern (Fig. 8A) while the pattern of the ubiquitous TATA-binding proteins remained unchanged throughout the same developmental period (Fig. 8B) , indicating that the developmental changes observed for MEF-2 and CArG-binding proteins (MEF-2 and BBF-1) in gel shift assays were not due to nonspecific losses in proteins during experimental procedures. MEF-2 and BBF-1 in early embryos are localized in early embryonic heart tube only. Since MEF-2 proteins are known to be present in both skeletal and cardiac muscle tissues (9, 42), we asked the question whether the MEF-2 activity observed in early embryos above is of cardiac origin. For this purpose, we FIG. 9. BBF-1 and MEF-2 are expressed only in the embryonic heart tube region of the stage 12 embryo. Protein extracts were prepared from the HFR of the stage 12 embryo and from the embryo free of HFR (see text). The extracts were assayed by gel shift assay with element B (MEF-2 site) DNA as probe. In order to ascertain the specificity of complexes, competitions were done with a 100-fold excess of nonradioactive element B DNA or an oligonucleotide containing a mutated element B sequence (61) . WE, whole embryo. isolated the heart tubes from several embryos at stage 12 of development ( Fig. 1) , at which time a well-defined heart tubular structure can be identified and excised microscopically free of the rest of embryonic tissues. Protein extracts pooled separately from several stage 12 heart tube (heart-forming region [HFR] ) and the remaining embryos (whole embryo-HFR) were compared for DNA binding. As shown in Fig. 9 , the gel shift pattern obtained from the heart tube region (HFR) alone is identical to that observed in extract from whole embryos ( Fig. 6 and 7) . The extract isolated from the remaining (heart-free) embryos (whole embryo-HFR), on the other hand, lacked both MEF-2 and BBF-1, but contained BBF-2 and BBF-3. As Fig. 1) (16, 21, 48) . The presumptive heart-forming cells begin to migrate from the lateral sides of the mesoderm, and as the development reaches stage 6, the migration becomes medial and rostrad and cells undergo considerable differentiation to form epicardium and endocardium. This is followed by fusion of epimyocardia, which subsequently fuse with the endocardium to form a linear heart tube at stage 10 (-33 h) (35) . Organized myofibrils appear, and rhythmic beating starts while the fusion is in progress. The precursors of skeletal muscle fibers, on the other hand, appear in somites within myotome (24) . The first somite, derived from the para-axial mesoderm, appears at stage 7, and the subsequent somite formation results from the budding of the mesoderm at regular intervals. Further changes lead to the formation of myotome, which gives rise to skeletal muscle at about stage 13 (24, 29) .
The purpose of the present experiments was to dissect the molecular events in early chicken embryonic development with respect to the expression of cardiac tissue-specific MLC2 gene transcript and the cognate transcription factors of the MEF-2 family which play a pivotal role in activation of its transcription (61) . Ventricular MLC2 gene was the experimental marker of choice for elucidation of tissue-specific regulation of gene activity, as it exhibits strict cardiac tissue specificity (2, 50, 54) . Although previous studies have characterized cardiogenesis by immunochemical and/or molecular approaches (6, 14, 17, 23, 37, 49, 58, 59 ), little information is available on molecular events in early stages of development during which the committed precardiac mesoderm enters cardiogenic differentiation. With a monoclonal antibody specific for sarcomeric MHCs, it was recently reported that MHC is the earliest muscle marker protein detectable as early as stage 7 in chicken development, i.e., approximately 8 h prior to myofibrillogenesis (22) . Our studies, employing the sensitive RT-PCR assay and single embryos of defined developmental stages, demonstrate that both cardiac MLC2 and cx-actin mRNAs can be discerned as early as stage 5, i.e., immediately after the cardiogenic fate assignment at stage 4 and at least 15 h prior to stage 9 and after, at which time myofibril formation begins. The short developmental interval (-1 h) between the cell commitment stage and activation of these genes leads one to speculate that these two events might be mediated by closely linked regulatory pathways and that the signal(s) which initiates cardiac tissue-specific gene expression becomes operative much earlier than was previously expected (59) . This would also be consistent with the interpretation that specification of the precardiac mesoderm and initiation of cardiogenic differentiation are temporally linked and may involve a common regulatory factor(s). Other characteristics of cardiac development, such as myofibril assembly and production of extracellular matrix, etc., must follow the expression of tissuespecific genes.
The onset of skeletal myogenic program follows that of cardiogenic program as exemplified by the appearance of skeletal MLC2 mRNA at stage 8 in comparison with cardiac MLC2 mRNA at stage 5 (Fig. 2) . That the temporal relationship between the appearance of these two mRNAs is physiologically relevant is demonstrated by the correspondence in appearance of skeletal muscle differentiation (stage 13) (24) with myofibrillogenesis (stage 10), at which time cardiac muscle contraction begins. This correlation and the fact that there are common genes expressed in skeletal and cardiac muscles would predict the existence of similar, if not identical, mechanisms for control of gene transcription in these two closely related tissue types. Yet, the cues responsible for activation of the respective (20, 28, 56) and are expressed in muscle tissues. It appears that MEF-2 activity is caused by a group of MEF-2 proteins, rather than by a single polypeptide. Some members of the MEF-2 family of proteins are tissue restricted, while others are ubiquitous (4, 31, 36, 38) . The fact that multiple isoforms of MEF-2 proteins, generated by alternatively spliced genes, which bind to functional DNA sites as dimers exist raises considerably their potential in executing diverse regulatory functions. Taken together, these observations strongly suggest that the MEF-2 proteins play a pivotal role in control of myogenesis and point to their potential as regulators of cell commitment (1, 4, 12, 36, 38) .
Partial sequence of a candidate cDNA clone for cardiac MEF-2 isolated in our laboratory shares a significant sequence homology in the C terminus (Fig. 4) 
